Price
$120.56+21.65%Social Signal Score
Analyst Ratings
45 analystsRevenue
$1.56B+376.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William J. Meury
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,844
- Beta
- 0.78
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 10.79
Financials
Revenue
$1.56B+376.9%Net Income
$-784.80M-8944.8%EBITDA
$-688.24M-1986.6%Free Cash Flow
$-690.95M-980.1%EPS (diluted)
$-3.86-7820.0%Shares Outstanding (diluted)
203.25M+4.1%Operating Expenses
$2.16BCash & Debt
$3.85BReturn of Capital
$0.00Revenue by Segment (annual)
$4.98BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.14B | $1.29B | $6.59 |
| 2024 | $4.24B | $32.62M | $0.16 |
| 2023 | $3.70B | $597.60M | $2.67 |
| 2022 | $3.39B | $340.66M | $1.53 |
| 2021 | $2.99B | $948.58M | $4.30 |
| 2020 | $2.67B | $-295.70M | $-1.36 |
| 2019 | $2.16B | $446.91M | $2.08 |
| 2018 | $1.88B | $109.49M | $0.52 |
| 2017 | $1.54B | $-313.14M | $-1.53 |
| 2016 | $1.11B | $104.22M | $0.55 |
| 2015 | $753.75M | $6.53M | $0.04 |
| 2014 | $511.50M | $-48.48M | $-0.29 |
| 2013 | $354.95M | $-83.15M | $-0.56 |
| 2012 | $297.06M | $-44.32M | $-0.34 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $9.68
- Implied price
- $145.27
- Return from $117.80
- 4.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $72.23 — -38.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -2.0% | -11.1% | -8.0% | -5.4% | -3.0% | -0.8% |
| 3.0% | -6.5% | -3.4% | -0.5% | 2.0% | 4.3% |
| 8.0% | -2.0% | 1.3% | 4.3% | 6.9% | 9.3% |
| 13.0% | 2.5% | 6.0% | 9.1% | 11.9% | 14.4% |
| 18.0% | 7.1% | 10.7% | 13.9% | 16.8% | 19.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
109+117.78%Social Signal Score
Mentions (48)
- Newsseekingalpha.com·5d ago·Positive
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newszacks.com·5d ago·Negative
INCY Wins European Commission Nod For Skin Disease Drug Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsreuters.com·6d ago·Neutral
Incyte says EU approves oral treatment for chronic skin disease Incyte says EU approves oral treatment for chronic skin disease
View source ↗ - Newsmarketbeat.com·11d ago·Negative
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030 Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of growth after 2029.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
View source ↗ - News (Marketaux)seekingalpha.com·19d ago·Neutral
Incyte Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:INCY) 2026-11-02 Incyte Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:INCY) 2026-11-02
View source ↗ - News (RSS)seekingalpha·23d ago·Neutral
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-over-year; Opzelura and hematology/oncology guidance increased, while Jakafi guidance remains unchanged.
View source ↗ - Newszacks.com·24d ago·Neutral
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
What Incyte (INCY) Said on Its Q3 Earnings Call Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.
View source ↗ - News (Marketaux)seekingalpha.com·24d ago·Neutral
Incyte Non-GAAP EPS of -$3.60 beats by $0.27, revenue of $1.56B beats by $100M (NASDAQ:INCY) Incyte Non-GAAP EPS of -$3.60 beats by $0.27, revenue of $1.56B beats by $100M (NASDAQ:INCY)
View source ↗ - Newszacks.com·24d ago·Neutral
Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs - Slideshow
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Incyte Corporation (INCY) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow
View source ↗ - Newsmarketbeat.com·27d ago·Neutral
Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”
View source ↗ - Newszacks.com·27d ago·Negative
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
View source ↗ - Newsbusinesswire.com·27d ago·Neutral
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.
View source ↗ - News (Marketaux)gurufocus.com·28d ago·Negative
Genmab (GMAB) and Incyte Launch Trial for KRAS G12D Colorectal Cancer Therapy Combo On October 25, 2026, Genmab AS (NASDAQ: [+252 characters]
View source ↗ - News (RSS)seekingalpha·28d ago·Neutral
Genmab, Incyte team up to develop experimental colorectal cancer treatment
View source ↗ - News (Marketaux)manilatimes.net·29d ago·Neutral
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer plus INCB161734 and standard-of-care che[+328 characters]
View source ↗ - Newsbusinesswire.com·29d ago·Neutral
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
View source ↗ - Newszacks.com·30d ago·Positive
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint? INCY's Q3'26 results hinge on Jakafi's strong sales, Opzelura's growth and rising royalties, while higher operating expenses may pressure earnings.
View source ↗ - Newsmarketbeat.com·30d ago·Negative
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option Prelude Therapeutics NASDAQ: PRLD outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026.
View source ↗ - Newsbusinesswire.com·40d ago·Neutral
Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community WILMINGTON, Del.--(BUSINESS WIRE)--Incyte today announced eight winners of the 2026 MPN Heroes® annual recognition program. The program, now in its 14th year, pays tribute to individuals whose contributions to patient care, research and advocacy make a meaningful difference for people affected by myeloproliferative neoplasms (MPNs). The 2026 Heroes join a distinguished group of over 100 p…
View source ↗ - Newszacks.com·53d ago·Neutral
INCY or TECH: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
View source ↗ - News (RSS)seekingalpha·57d ago·Neutral
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
View source ↗ - Newsbusinesswire.com·58d ago·Neutral
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva.
View source ↗ - News (RSS)investing·63d ago·Neutral
Specialised Therapeutics expands Incyte partnership to Australia
View source ↗ - Newsmarketbeat.com·64d ago·Negative
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·69d ago·Positive
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold? Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (Marketaux)seekingalpha.com·75d ago·Positive
Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms (NASDAQ:INCY) Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms (NASDAQ:INCY)
View source ↗ - News (RSS)seekingalpha·81d ago·Negative
Incyte Corporation: Why Jakafi Is No Longer The Real Story Here
View source ↗ - Newsseekingalpha.com·81d ago·Neutral
…e assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.
View source ↗ - News (Marketaux)gurufocus.com·82d ago·Positive
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Access to Jakafi Incyte Corporation INC[+245 characters]
View source ↗ - News (RSS)yahoo·86d ago·Neutral
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
View source ↗ - Newszacks.com·87d ago·Neutral
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue? Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)yahoo·96d ago·Neutral
Incyte Stock: Is Wall Street Bullish or Bearish?
View source ↗ - News (RSS)yahoo·102d ago·Positive
Incyte Sales Growth Drives Share Price Gains
View source ↗ - Newsfxempire.com·102d ago·Positive
Incyte Sales Growth Drives Share Price Gains Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.
View source ↗ - Newsbusinesswire.com·107d ago·Neutral
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $1.91 per share
Typical surprise +14.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$-3.60 vs $-3.93beat
- Tue, Jul 28$3.09 vs $2.15beat
- Tue, Apr 28$1.81 vs $1.34beat
- Tue, Feb 10$1.80 vs $1.90miss
- Tue, Oct 28$2.26 vs $1.66beat
- Tue, Jul 29$1.57 vs $1.39beat
Estimates and results for INCY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INCY officers and directors.
- Bought
- —
- Sold
- $41.8m
0 trades
24 trades
- Stein Steven Hsold
- Cagnoni Pablo Jsold
- Cagnoni Pablo Jsold
- Heeson Leesold
- Heeson Leesold
- Heeson Leesold
- Heeson Leesold
- Heeson Leesold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (11d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (15d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 7, 2023 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (20d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 14, 2020 (28d later)Buy$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Dec 8, 2018 (26d later)Sell$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Oct 6, 2017 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
